SUBSCRIBE
SUBSCRIBE
Greg Slabodkin

Greg Slabodkin

Greg is a seasoned editor/writer who has covered the healthcare, life sciences and medical device industries for several tech trade publications. He is the recipient of a Post-Newsweek Business Information Editorial Excellence Award for his news reporting and a Gold Award for Best Case Study from the American Society of Healthcare Publication Editors. In addition, Greg is a Healthcare Fellow from the Society for Advancing Business Editing and Writing. He is an avid Buffalo Bills football fan, likes to kayak and plays guitar.

Pictured: 3D illustration of a DNA double-helix
Drug Development
ASGCT24: Prime Medicine to Apply Gene Editing to Wide-Ranging Indications
The biotech touted its prime editing technology at ASGCT on Tuesday after receiving FDA clearance last week for a clinical study of a drug candidate based on the platform.
May 7, 2024
 · 
2 min read
 · 
Greg Slabodkin
Pictured: Baltimore skyline with color treatment
Drug Development
ASGCT 2024 Comes at Pivotal Time for Gene and Cell Therapy Sector
Jeffrey Chamberlain, president of the American Society of Gene & Cell Therapy, spoke with BioSpace about what we can expect to learn about in Baltimore this week.
May 3, 2024
 · 
6 min read
 · 
Greg Slabodkin
Pictured: An illustration of colored arrows climbing a wall
Drug Development
Novo Nordisk’s Wegovy Pricing Drops as Competition Heats Up with Eli Lilly
It wasn’t calls from lawmakers but market competition with Eli Lilly’s Zepbound that prompted Novo Nordisk to lower the prices of its blockbuster weight-loss drug.
May 3, 2024
 · 
3 min read
 · 
Greg Slabodkin
Pictured: A Bristol Myers Squibb among some bushes
Business
BMS Decision to Lay Off 2,200 Employees Comes After M&A Spending Spree
Is there a connection between Bristol Myers Squibb’s announcement that it will reduce its headcount by 6% and the company’s recent acquisitions of Karuna, Mirati and RayzeBio?
April 26, 2024
 · 
2 min read
 · 
Greg Slabodkin
Pictured: An illustration of human hands holding u
Business
J&J, Other Q1 Financials Beg the Question: What Does It Mean to Miss Expectations?
If a company’s final sales end up falling short of the consensus analyst estimate, then they have missed their number. Johnson & Johnson was close in the first quarter of 2024 but ultimately no cigar.
April 19, 2024
 · 
2 min read
 · 
Greg Slabodkin
Pictured: Illustration of migrating cancer cells
AACR, Cancer Treatment and the Promise of Antibody-Drug Conjugates
This week’s American Association for Cancer Research annual meeting drove home the importance of antibody-drug conjugates as an emerging class of potential anti-cancer therapeutics.
April 12, 2024
 · 
3 min read
 · 
Greg Slabodkin
U.S. and Chinese flags in concrete, broken in the middle
Policy
US National Security, China and Biotechnology in 2024
Recent warnings about Chinese biopharma partners from members of Congress and U.S. intelligence officials have reached a fever pitch in Washington.
April 5, 2024
 · 
4 min read
 · 
Greg Slabodkin
Pictured: A pharmacist ringing up a prescription m
Policy
The IRA, Medicare and the High Costs of GLP-1 Drugs Like Wegovy
Sanders says he wants Novo Nordisk to “do the right thing” and lower the costs of Ozempic and Wegovy. But only the Inflation Reduction Act can achieve that.
March 29, 2024
 · 
3 min read
 · 
Greg Slabodkin
Pictured: Weight loss scale and pile of money/Tayl
Policy
The Time Has Come to Make Weight-Loss Drugs Available to Those Who Need Them
Oprah Winfrey this week shone the spotlight on these transformative GLP-1 medications. Now, it’s time for Medicare to cover them and expand access to millions of Americans.
March 22, 2024
 · 
3 min read
 · 
Greg Slabodkin
Pictured: Illustration of alphabetical letters ris
FDA
NASH or MASH: No Matter What You Call It, Madrigal’s FDA Approval Is a Big Deal
If you’re confused by the NASH versus MASH indication, you’re not alone.
March 15, 2024
 · 
3 min read
 · 
Greg Slabodkin
Pictured: A fork in a dirt road/iStock, by-studio
Business
Alkermes and Jazz: Two Different Approaches to Neuroscience, Oncology Portfolios
Alkermes spun off its oncology business in late 2023 to become a pure-play neuroscience company, while Jazz Pharmaceuticals continues to invest in and focus on both of its businesses.
March 11, 2024
 · 
3 min read
 · 
Greg Slabodkin
Pictured: American flag flying in front of the Cap
Policy
Biden Turns Up Heat on Big Pharma’s Drug Prices in State of the Union Address
President Biden called for expanding the Inflation Reduction Act to lower prescription drug prices. What would Trump do if he wins the 2024 election?
March 8, 2024
 · 
5 min read
 · 
Greg Slabodkin
The ABCs of ADCs: Why antibody-drug conjugates are so hot right now
These days you can hardly move without figuratively bumping into ⁠antibody-drug conjugates⁠ (ADCs). This week we discuss ⁠Pfizer’s strategic priorities⁠ for oncology - focused on ADCs and less on small molecules - and how the market is being influenced by the IRA.
March 6, 2024
 · 
1 min read
 · 
Lori Ellis
Pictured: Entrance to Pfizer's office in Belgium
Policy
IRA Drives Pfizer’s Decision to Focus on Biologics, Not Small Molecules
Pfizer’s oncology strategy to build up its biologics portfolio and dramatically reduce small molecules was influenced by the Inflation Reduction Act’s drug price negotiation provisions.
March 4, 2024
 · 
4 min read
 · 
Greg Slabodkin
Pictured: A green, blue and pink ribbon representi
Business
Rare Disease Day Reminds Biopharma of Opportunities, Challenges
The annual observance highlights how far the industry has come and serves as a wake-up call for how far it must still go to meet the needs of patients with rare diseases.
March 1, 2024
 · 
3 min read
 · 
Greg Slabodkin
Load More